Testing a new injection to reduce lung disease flare-ups

Plain-English translation of NCT07402551 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether Injection can help people with moderate to severe COPD (a progressive lung disease that makes breathing difficult) experience fewer flare-ups and improve their lung function. Half of the participants will receive the medication, and half will receive a placebo (an inactive shot that looks identical) so researchers can fairly measure how well the treatment works. The study will track participants for one full year.

Many people with severe COPD continue to have frequent flare-ups even when taking standard medications, which seriously impacts their quality of life and ability to do daily activities. This trial is exploring whether this medication could help reduce those flare-ups and improve breathing for patients who need better control of their disease.

Do you qualify?

You likely qualify if…

you are between 40 and 85 years old
you have been diagnosed with COPD for at least 12 months
you have had at least 2 moderate or 1 severe COPD flare-up in the past year
you have a history of smoking or exposure to lung irritants
you are currently taking triple therapy (three standard COPD medications combined) for at least 3 months
you have a specific blood marker (eosinophils at 150/mm³ or higher) that suggests you may respond to this treatment

You likely don't qualify if…

you have been diagnosed with asthma or have a history of asthma
you have other serious lung diseases besides COPD
you have a history of cancer or autoimmune disease
you have untreated hepatitis B or C, HIV, or other active infections
you are currently using long-term oxygen therapy or mechanical ventilation

What participation looks like

You will visit the study clinic regularly over 52 weeks (one year) and receive an injection of either the study medication or placebo every two weeks. At various visits, the team will measure your lung function with breathing tests, check blood markers, track how many flare-ups you have, and assess how much your shortness of breath has improved. You'll also need to continue taking your regular COPD medications throughout the study.

AI-generated summary from trial data · Jul 20, 2026 · Not medical advice

Trial locations(42 sites)

China

Anhui Provincial Chest Hospital, Hefei, Anhui

Wan Bei General Hospital of Wanbei Coal power Group, Suzhou, Anhui

The Affiliated Bishan Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality

Zhongshan Hospital Xiamen University, Xiamen, Fujian

The first affiliated hospital of guangzhou medical university, Guangzhou, Guangdong